{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:19:12Z","timestamp":1790605152981,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000320","name":"Alzheimer's Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer's Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In addition to the core clinical features of fluctuating cognition, visual hallucinations, and parkinsonism, individuals with dementia with Lewy bodies (DLB) frequently experience chronic and debilitating major depression. Treatment of depression in DLB is hampered by a lack of available effective therapies and standard serotonergic medication for major depressive disorder (MDD) is typically ineffective. Dysfunction of dopaminergic neurotransmission contributing to anhedonia and loss of motivation has been described in MDD. The subgenual anterior cingulate cortex (sgACC) is important in mood regulation and in the symptomatic expression of depression, displaying structural, functional and metabolic abnormalities in MDD. To assess dopaminergic and serotonergic synaptic changes in DLB, post mortem sgACC tissue from DLB donors with and without depression was investigated using high-resolution stimulated emission depletion (STED) microscopy, as well as Western and dot blotting techniques. STED imaging demonstrated the presence of \u03b1-synuclein within individual dopaminergic terminals in the sgACC, \u03b1-synuclein presence showing a significant positive correlation with increased synaptosomal associated protein 25\u2009kDa (SNAP25) volumes in depressed DLB cases. A reduction in dopaminergic innervation in the sgACC was observed in DLB cases with depression compared to controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), but not in non-depressed DLB donors, along with reduced levels of multiple dopaminergic markers and receptors. Limited alterations were observed in serotonergic markers. Our work demonstrates a role for dopaminergic neurotransmission in the aetiology of depression in DLB. Careful and selective targeting of dopaminergic systems in the sgACC may be a therapeutic option for treatment of depression in DLB.\n                  <\/jats:p>","DOI":"10.1038\/s41398-025-03298-3","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T11:08:28Z","timestamp":1742468908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5923-1811","authenticated-orcid":false,"given":"Lina","family":"Gliaudelyt\u0117","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rushton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Berlinguer-Palmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-0993","authenticated-orcid":false,"given":"Christopher M.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"3298_CR1","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863\u201372.","journal-title":"Neurology"},{"key":"3298_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nan.12664","volume":"46","author":"KE McAleese","year":"2020","unstructured":"McAleese KE, Colloby S, Attems J, Thomas A, Francis PT. Mixed brain pathologies account for most dementia in the brains for dementia research cohort. Neuropathol Appl Neurobiol. 2020;46:24\u201324.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3298_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"3298_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00702-023-02669-8","volume":"130","author":"KA Jellinger","year":"2023","unstructured":"Jellinger KA. Depression in dementia with lewy bodies: a critical update. J Neural Transm. 2023;130:1207\u201318.","journal-title":"J Neural Transm"},{"key":"3298_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ggi.12466","volume":"15","author":"H Fujishiro","year":"2015","unstructured":"Fujishiro H, Nakamura S, Sato K, Iseki E. Prodromal dementia with lewy bodies. Geriatr Gerontol Int. 2015;15:817\u201326.","journal-title":"Geriatr Gerontol Int"},{"key":"3298_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-016-0171-4","volume":"8","author":"MH Breitve","year":"2016","unstructured":"Breitve MH, Hynninen MJ, Bronnick K, Chwiszczuk LJ, Auestad BH, Aarsland D, et al. A longitudinal study of anxiety and cognitive decline in dementia with lewy bodies and Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:3.","journal-title":"Alzheimers Res Ther"},{"key":"3298_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01892-9","volume":"22","author":"A Joshi","year":"2022","unstructured":"Joshi A, Todd S, Finn DP, McClean PL, Wong-Lin K. Multi-dimensional relationships among dementia, depression and prescribed drugs in England and wales hospitals. BMC Med Inform Decis Mak. 2022;22:262.","journal-title":"BMC Med Inform Decis Mak"},{"key":"3298_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.biopsych.2006.09.020","volume":"62","author":"MD Greicius","year":"2007","unstructured":"Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry. 2007;62:429\u201337.","journal-title":"Biol Psychiatry"},{"key":"3298_CR9","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1002\/hbm.25001","volume":"41","author":"F Scharnowski","year":"2020","unstructured":"Scharnowski F, Nicholson AA, Pichon S, Rosa MJ, Rey G, Eickhoff SB, et al. The role of the subgenual anterior cingulate cortex in dorsomedial prefrontal-amygdala neural circuitry during positive-social emotion regulation. Hum Brain Mapp. 2020;41:3100\u201318.","journal-title":"Hum Brain Mapp"},{"key":"3298_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1017\/S1092852900013754","volume":"13","author":"WC Drevets","year":"2008","unstructured":"Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 2008;13:663\u201381.","journal-title":"CNS Spectr"},{"key":"3298_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2014.02.016","volume":"159","author":"MT Berlim","year":"2014","unstructured":"Berlim MT, McGirr A, Van den Eynde F, Fleck MP, Giacobbe P. Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual cingulate cortex for treatment-resistant depression: a systematic review and exploratory meta-analysis. J Affect Disord. 2014;159:31\u201338.","journal-title":"J Affect Disord"},{"key":"3298_CR12","doi-asserted-by":"crossref","first-page":"173s","DOI":"10.1016\/j.biopsych.2010.05.023","volume":"69","author":"SJ Rizvi","year":"2011","unstructured":"Rizvi SJ, Kennedy SH, Giacobbe P, Mayberg HS, Lozano AM. Subgenual cingulate gyrus deep brain stimulation for refractory major depressive disorder: differences in FDG-PET between responders and non-responders. Biol Psychiatry. 2011;69:173s\u2013173s.","journal-title":"Biol Psychiatry"},{"key":"3298_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.v61n0405","volume":"61","author":"RM Hirschfeld","year":"2000","unstructured":"Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61:4\u20136.","journal-title":"J Clin Psychiatry"},{"key":"3298_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1025-0","volume":"16","author":"L Wang","year":"2016","unstructured":"Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16:319.","journal-title":"BMC Psychiatry"},{"key":"3298_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.neuropharm.2011.07.043","volume":"62","author":"C Baeken","year":"2012","unstructured":"Baeken C, De Raedt R, Bossuyt A. Is treatment-resistance in unipolar melancholic depression characterized by decreased serotonin(2)A receptors in the dorsal prefrontal - anterior cingulate cortex? Neuropharmacology. 2012;62:340\u20136.","journal-title":"Neuropharmacology"},{"key":"3298_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1371\/journal.pmed.0020392","volume":"2","author":"JR Lacasse","year":"2005","unstructured":"Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005;2:1211\u20136.","journal-title":"PLoS Med"},{"key":"3298_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neubiorev.2015.01.018","volume":"51","author":"PW Andrews","year":"2015","unstructured":"Andrews PW, Bharwani A, Lee KR, Fox M, Thomson JA. Is serotonin an upper or a downer? the evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci Biobehav Rev. 2015;51:164\u201388.","journal-title":"Neurosci Biobehav Rev"},{"key":"3298_CR18","first-page":"1852","volume":"30","author":"F Torun","year":"2010","unstructured":"Torun F, Bayulkem K, Torun SD. Efficacy of sertraline in the treatment of depression in patients with Parkinson\u2019s disease. Turkiye Klinikleri Tip Bilimleri Dergisi. 2010;30:1852\u20137.","journal-title":"Turkiye Klinikleri Tip Bilimleri Dergisi"},{"key":"3298_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","volume":"253","author":"P Barone","year":"2006","unstructured":"Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601\u20137.","journal-title":"J Neurol"},{"key":"3298_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.neuron.2015.04.015","volume":"86","author":"M Pignatelli","year":"2015","unstructured":"Pignatelli M, Bonci A. Role of dopamine neurons in reward and aversion: a synaptic plasticity perspective. Neuron. 2015;86:1145\u201357.","journal-title":"Neuron"},{"key":"3298_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11713","volume":"493","author":"D Chaudhury","year":"2013","unstructured":"Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature. 2013;493:532\u20136.","journal-title":"Nature"},{"key":"3298_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pscychresns.2006.03.001","volume":"147","author":"M Sarchiapone","year":"2006","unstructured":"Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res. 2006;147:243\u20138.","journal-title":"Psychiatry Res"},{"key":"3298_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0006-3223(94)91202-5","volume":"35","author":"HA D\u2019Haenen","year":"1994","unstructured":"D\u2019Haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994;35:128\u201332.","journal-title":"Biol Psychiatry"},{"key":"3298_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314\u201322.","journal-title":"Brain"},{"key":"3298_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jagp.2020.12.009","volume":"29","author":"NM Fischer","year":"2021","unstructured":"Fischer NM, Hinkle JT, Perepezko K, Bakker CC, Morris M, Broen MPG, et al. Brainstem pathologies correlate with depression and psychosis in Parkinson\u2019s disease. Am J Geriatr Psychiatry. 2021;29:958\u201368.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3298_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bpa.12697","volume":"29","author":"L Patterson","year":"2018","unstructured":"Patterson L, Rushton SP, Attems J, Thomas AJ, Morris CM. Degeneration of dopaminergic circuitry influences depressive symptoms in lewy body disorders. Brain Pathol. 2018;29:544\u201357.","journal-title":"Brain Pathol"},{"key":"3298_CR27","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1017\/S0033291714000841","volume":"44","author":"E Rodriguez-Cano","year":"2014","unstructured":"Rodriguez-Cano E, Sarro S, Monte GC, Maristany T, Salvador R, McKenna PJ, et al. Evidence for structural and functional abnormality in the subgenual anterior cingulate cortex in major depressive disorder. Psychol Med. 2014;44:3263\u201373.","journal-title":"Psychol Med"},{"key":"3298_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnen\/nlz047","volume":"78","author":"L Patterson","year":"2019","unstructured":"Patterson L, Firbank MJ, Colloby SJ, Attems J, Thomas AJ, Morris CM. Neuropathological changes in dementia with lewy bodies and the cingulate Island sign. J Neuropathol Exp Neurol. 2019;78:717\u201324.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3298_CR29","doi-asserted-by":"publisher","first-page":"pdb.top071803","DOI":"10.1101\/pdb.top071803","volume":"2013","author":"MJ West","year":"2013","unstructured":"West MJ. Isotropy, iSectors, and vertical sections in stereology. Cold Spring Harb Protoc. 2013;2013:pdb.top071803.","journal-title":"Cold Spring Harb Protoc"},{"key":"3298_CR30","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/cne.24468","volume":"526","author":"V Delic","year":"2018","unstructured":"Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D, et al. Sensitivity and specificity of phospho-Ser129 alpha-synuclein monoclonal antibodies. J Comp Neurol. 2018;526:1978\u201390.","journal-title":"J Comp Neurol"},{"key":"3298_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0092-8674(91)90184-Z","volume":"67","author":"A Szabo","year":"1991","unstructured":"Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and sex-lethal. Cell. 1991;67:325\u201333.","journal-title":"Cell"},{"key":"3298_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/(SICI)1096-9861(20000529)421:2<172::AID-CNE4>3.0.CO;2-8","volume":"421","author":"LJ Freedman","year":"2000","unstructured":"Freedman LJ, Insel TR, Smith Y. Subcortical projections of area 25 (subgenual cortex) of the macaque monkey. J Comp Neurol. 2000;421:172\u201388.","journal-title":"J Comp Neurol"},{"key":"3298_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1227\/NEU.0000000000001315","volume":"79","author":"F Vergani","year":"2016","unstructured":"Vergani F, Martino J, Morris C, Attems J, Ashkan K, Dell\u2019Acqua F. Anatomic connections of the subgenual cingulate region. Neurosurgery. 2016;79:465\u201372.","journal-title":"Neurosurgery"},{"key":"3298_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cne.902050107","volume":"205","author":"LJ Porrino","year":"1982","unstructured":"Porrino LJ, Goldman-Rakic PS. Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J Comp Neurol. 1982;205:63\u201376.","journal-title":"J Comp Neurol"},{"key":"3298_CR35","doi-asserted-by":"publisher","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","volume":"111","author":"J Burre","year":"2014","unstructured":"Burre J, Sharma M, Sudhof TC. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA. 2014;111:E4274\u20134283.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3298_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neurobiolaging.2022.05.007","volume":"117","author":"PV Nunes","year":"2022","unstructured":"Nunes PV, Suemoto CK, Rodriguez RD, Paraizo Leite RE, Nascimento C, Pasqualucci CA, et al. Neuropathology of depression in non-demented older adults: a large postmortem study of 741 individuals. Neurobiol Aging. 2022;117:107\u201316.","journal-title":"Neurobiol Aging"},{"key":"3298_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","volume":"10","author":"I Rektorov\u00e1","year":"2003","unstructured":"Rektorov\u00e1 I, Rektor I, Bares M, Dost\u00e1l V, Ehler E, Fanfrdlov\u00e1 Z, et al. Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease:: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399\u2013406.","journal-title":"Eur J Neurol"},{"key":"3298_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/jrms.jrms_790_21","volume":"27","author":"E Ziaei","year":"2022","unstructured":"Ziaei E, Ardestani PE, Chitsaz A. Comparison of pramipexole and citalopram in the treatment of depression in Parkinson\u2019s disease: a randomized parallel-group trial. J Res Med Sci. 2022;27:55.","journal-title":"J Res Med Sci"},{"key":"3298_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/brain\/awaa002","volume":"143","author":"AE Whitton","year":"2020","unstructured":"Whitton AE, Reinen JM, Slifstein M, Ang YS, McGrath PJ, Iosifescu DV, et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain. 2020;143:701\u201310.","journal-title":"Brain"},{"key":"3298_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","volume":"4","author":"L Lattanzi","year":"2002","unstructured":"Lattanzi L, Dell\u2019Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307\u201314.","journal-title":"Bipolar Disord"},{"key":"3298_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1006\/exnr.1997.6418","volume":"144","author":"DA McRitchie","year":"1997","unstructured":"McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson\u2019s disease. Exp Neurol. 1997;144:202\u201313.","journal-title":"Exp Neurol"},{"key":"3298_CR42","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease. J Neuropathol Exp Neurol. 1991;50:743\u201355.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3298_CR43","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1001\/jamapsychiatry.2013.2224","volume":"70","author":"RS Wilson","year":"2013","unstructured":"Wilson RS, Nag S, Boyle PA, Hizel LP, Yu L, Buchman AS, et al. Brainstem aminergic nuclei and late-life depressive symptoms. JAMA Psychiatry. 2013;70:1320\u20138.","journal-title":"JAMA Psychiatry"},{"key":"3298_CR44","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/ene.15890","volume":"30","author":"HYY Wang","year":"2023","unstructured":"Wang HYY, Zhao YB, Schrag A. Development of anxiety in early Parkinson\u2019s disease: a clinical and biomarker study. Eur J Neurol. 2023;30:2661\u20138.","journal-title":"Eur J Neurol"},{"key":"3298_CR45","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.20226","volume":"56","author":"GW Ross","year":"2004","unstructured":"Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004;56:532\u20139.","journal-title":"Ann Neurol"},{"key":"3298_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and huntington. clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415\u201355.","journal-title":"J Neurol Sci"},{"key":"3298_CR47","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","volume":"51","author":"O Hornykiewicz","year":"1998","unstructured":"Hornykiewicz O. Biochemical aspects of Parkinson\u2019s disease. Neurology. 1998;51:S2\u20139.","journal-title":"Neurology"},{"key":"3298_CR48","doi-asserted-by":"publisher","first-page":"11113","DOI":"10.1073\/pnas.1903049116","volume":"116","author":"J Sun","year":"2019","unstructured":"Sun J, Wang L, Bao H, Premi S, Das U, Chapman ER, et al. Functional cooperation of alpha-synuclein and VAMP2 in synaptic vesicle recycling. Proc Natl Acad Sci USA. 2019;116:11113\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3298_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41531-018-0044-6","volume":"4","author":"AK Reeve","year":"2018","unstructured":"Reeve AK, Grady JP, Cosgrave EM, Bennison E, Chen C, Hepplewhite PD, et al. Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2018;4:9.","journal-title":"NPJ Parkinsons Dis"},{"key":"3298_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57\u201371.","journal-title":"Neuron"},{"key":"3298_CR51","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awu057","volume":"137","author":"E Rockenstein","year":"2014","unstructured":"Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, et al. Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain. 2014;137:1496\u2013513.","journal-title":"Brain"},{"key":"3298_CR52","doi-asserted-by":"publisher","first-page":"e0195339","DOI":"10.1371\/journal.pone.0195339","volume":"13","author":"MG Choi","year":"2018","unstructured":"Choi MG, Kim MJ, Kim DG, Yu R, Jang YN, Oh WJ. Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. PLoS ONE. 2018;13:e0195339.","journal-title":"PLoS ONE"},{"key":"3298_CR53","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/01.WNL.0000123248.39847.1D","volume":"62","author":"Z Walker","year":"2004","unstructured":"Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62:1568\u201372.","journal-title":"Neurology"},{"key":"3298_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13195-014-0052-7","volume":"6","author":"M Marquie","year":"2014","unstructured":"Marquie M, Locascio JJ, Rentz DM, Becker JA, Hedden T, Johnson KA, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014;6:52.","journal-title":"Alzheimers Res Ther"},{"key":"3298_CR55","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/life13041043","volume":"13","author":"A Tundo","year":"2023","unstructured":"Tundo A, Betro\u2019 S, de Filippis R, Marchetti F, Nacca D, Necci R, et al. Pramipexole augmentation for treatment-resistant unipolar and bipolar depression in the real world: a systematic review and meta-analysis. Life. 2023;13:1043.","journal-title":"Life"},{"key":"3298_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/acps.13055","volume":"140","author":"A Tundo","year":"2019","unstructured":"Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. a systematic review and meta-analysis. Acta Psychiatr Scand. 2019;140:116\u201325.","journal-title":"Acta Psychiatr Scand"},{"key":"3298_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5:25\u201343.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"3298_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","volume":"719","author":"GM Leggio","year":"2013","unstructured":"Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F, et al. Dopamine D-3 receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013;719:25\u201333.","journal-title":"Eur J Pharmacol"},{"key":"3298_CR59","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0006-8993(93)90414-I","volume":"600","author":"JN Joyce","year":"1993","unstructured":"Joyce JN. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. results in Parkinson\u2019s disease cases. Brain Res. 1993;600:156\u201360.","journal-title":"Brain Res"},{"key":"3298_CR60","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archneur.58.3.466","volume":"58","author":"RA Sweet","year":"2001","unstructured":"Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58:466\u201372.","journal-title":"Arch Neurol"},{"key":"3298_CR61","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/brain\/122.8.1449","volume":"122","author":"MA Piggott","year":"1999","unstructured":"Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with lewy bodies, Alzheimer\u2019s and Parkinson\u2019s diseases: rostrocaudal distribution. Brain. 1999;122:1449\u201368.","journal-title":"Brain"},{"key":"3298_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","volume":"31","author":"AF Leentjens","year":"2009","unstructured":"Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson\u2019s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31:89\u201398.","journal-title":"Clin Ther"},{"key":"3298_CR63","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26:S42\u201380.","journal-title":"Mov Disord"},{"key":"3298_CR64","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.neuropsychologia.2009.01.039","volume":"47","author":"A Costa","year":"2009","unstructured":"Costa A, Peppe A, Dell\u2019Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson\u2019s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009;47:1374\u201381.","journal-title":"Neuropsychologia"},{"key":"3298_CR65","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/cjn.2018.21","volume":"45","author":"MA Roy","year":"2018","unstructured":"Roy MA, Doiron M, Talon-Croteau J, Dupre N, Simard M. Effects of antiparkinson medication on cognition in parkinson\u2019s disease: a systematic review. Can J Neurol Sci. 2018;45:375\u2013404.","journal-title":"Can J Neurol Sci"},{"key":"3298_CR66","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00018-010-0293-y","volume":"67","author":"P Rondou","year":"2010","unstructured":"Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci. 2010;67:1971\u201386.","journal-title":"Cell Mol Life Sci"},{"key":"3298_CR67","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/sj.npp.1300677","volume":"30","author":"AM Basso","year":"2005","unstructured":"Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, et al. Antidepressant-like effect of D(2\/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology. 2005;30:1257\u201368.","journal-title":"Neuropsychopharmacology"},{"key":"3298_CR68","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/pcn.13436","volume":"76","author":"M Mizutani","year":"2022","unstructured":"Mizutani M, Sano T, Ohira M, Takao M. Neuropathological studies of serotonergic and noradrenergic systems in lewy body disease patients with delusion or depression. Psychiatry Clin Neurosci. 2022;76:459\u201367.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3298_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bpa.12168","volume":"25","author":"K Seidel","year":"2015","unstructured":"Seidel K, Mahlke J, Siswanto S, Kruger R, Heinsen H, Auburger G, et al. The brainstem pathologies of Parkinson\u2019s disease and dementia with lewy bodies. Brain Pathol. 2015;25:121\u201335.","journal-title":"Brain Pathol"},{"key":"3298_CR70","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease. Brain Res. 1990;510:104\u20137.","journal-title":"Brain Res"},{"key":"3298_CR71","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00401-007-0260-3","volume":"114","author":"EE Benarroch","year":"2007","unstructured":"Benarroch EE, Schmeichel AM, Sandroni P, Parisi JE, Low PA. Rostral raphe involvement in lewy body dementia and multiple system atrophy. Acta Neuropathol. 2007;114:213\u201320.","journal-title":"Acta Neuropathol"},{"key":"3298_CR72","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cell.2018.07.043","volume":"175","author":"J Ren","year":"2018","unstructured":"Ren J, Friedmann D, Xiong J, Liu CD, Ferguson BR, Weerakkody T, et al. Anatomically defined and functionally distinct dorsal raphe serotonin sub-systems. Cell. 2018;175:472\u201387. e420","journal-title":"Cell"},{"key":"3298_CR73","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1093\/brain\/awv215","volume":"138","author":"Z Qamhawi","year":"2015","unstructured":"Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson\u2019s disease. Brain. 2015;138:2964\u201373.","journal-title":"Brain"},{"key":"3298_CR74","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet A, Krack P, Lhommee E, Metereau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain. 2016;139:2486\u2013502.","journal-title":"Brain"},{"key":"3298_CR75","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"M Guttman","year":"2007","unstructured":"Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease. Eur J Neurol. 2007;14:523\u20138.","journal-title":"Eur J Neurol"},{"key":"3298_CR76","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/mds.28722","volume":"36","author":"A Maillet","year":"2021","unstructured":"Maillet A, Metereau E, Tremblay L, Favre E, Klinger H, Lhommee E, et al. Serotonergic and dopaminergic lesions underlying parkinsonian neuropsychiatric signs. Mov Disord. 2021;36:2888\u20132900.","journal-title":"Mov Disord"},{"key":"3298_CR77","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","volume":"40","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216\u201321.","journal-title":"Neurobiol Dis"},{"key":"3298_CR78","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain. 2008;131:120\u201331.","journal-title":"Brain"},{"key":"3298_CR79","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/mds.22212","volume":"23","author":"I Boileau","year":"2008","unstructured":"Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson\u2019s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776\u201380.","journal-title":"Mov Disord"},{"key":"3298_CR80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jad.2015.07.034","volume":"186","author":"JP Kambeitz","year":"2015","unstructured":"Kambeitz JP, Howes OD. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358\u201366.","journal-title":"J Affect Disord"},{"key":"3298_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2020.07.008","volume":"78","author":"N Nicastro","year":"2020","unstructured":"Nicastro N, Fleury V, Broc N, Burkhard PR, Garibotto V. Extrastriatal (123)I-FP-CIT SPECT impairment in degenerative parkinsonisms. Parkinsonism Relat Disord. 2020;78:38\u201343.","journal-title":"Parkinsonism Relat Disord"},{"key":"3298_CR82","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.nicl.2019.102062","volume":"25","author":"JJ van der Zande","year":"2020","unstructured":"van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, et al. Serotonergic deficits in dementia with lewy bodies with concomitant Alzheimer\u2019s disease pathology: an (123)I-FP-CIT SPECT study. Neuroimage Clin. 2020;25:102062.","journal-title":"Neuroimage Clin"},{"key":"3298_CR83","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00259-019-04324-5","volume":"46","author":"A Pilotto","year":"2019","unstructured":"Pilotto A, Schiano di Cola F, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson\u2019s disease and in dementia with lewy bodies: a (123)I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2019;46:1642\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3298_CR84","doi-asserted-by":"publisher","first-page":"101755","DOI":"10.1016\/j.nicl.2019.101755","volume":"22","author":"M Joling","year":"2019","unstructured":"Joling M, Vriend C, Raijmakers P, van der Zande JJ, Lemstra AW, Berendse HW, et al. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson\u2019s disease and dementia with lewy bodies, compared with healthy controls: an (123)I-FP-CIT SPECT study. Neuroimage Clin. 2019;22:101755.","journal-title":"Neuroimage Clin"},{"key":"3298_CR85","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acn3.246","volume":"2","author":"C Buddhala","year":"2015","unstructured":"Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2015;2:949\u201359.","journal-title":"Ann Clin Transl Neurol"},{"key":"3298_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0165-0327(00)00375-X","volume":"69","author":"C Ballard","year":"2002","unstructured":"Ballard C, Johnson M, Piggott M, Perry R, O\u2019Brien J, Rowan E, et al. A positive association between 5HT re-uptake binding sites and depression in dementia with lewy bodies. J Affect Disord. 2002;69:219\u201323.","journal-title":"J Affect Disord"},{"key":"3298_CR87","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00415-009-5247-7","volume":"256","author":"PT Francis","year":"2009","unstructured":"Francis PT. Biochemical and pathological correlates of cognitive and behavioural change in DLB\/PDD. J Neurol. 2009;256:280\u20135.","journal-title":"J Neurol"},{"key":"3298_CR88","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000161058","volume":"26","author":"SI Sharp","year":"2008","unstructured":"Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with lewy bodies and Parkinson\u2019s disease dementia. Dement Geriatr Cogn Disord. 2008;26:330\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3298_CR89","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/0022-510X(91)90193-B","volume":"106","author":"AV Cheng","year":"1991","unstructured":"Cheng AV, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, et al. Cortical serotonin-S2 receptor binding in lewy body dementia, Alzheimer\u2019s and Parkinson\u2019s diseases. J Neurol Sci. 1991;106:50\u201355.","journal-title":"J Neurol Sci"},{"key":"3298_CR90","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","volume":"55","author":"EK Perry","year":"1990","unstructured":"Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in lewy body dementia. J Neurochem. 1990;55:1454\u20136.","journal-title":"J Neurochem"},{"key":"3298_CR91","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology. 2010;35:881\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"3298_CR92","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340.","journal-title":"Lancet"},{"key":"3298_CR93","first-page":"8","volume":"52","author":"B Dirks","year":"2022","unstructured":"Dirks B, Fava M, Atkinson SD, Joyce M, Thase ME, Howell B, et al. Adjunctive pimavanserin in patients with major depressive disorder: combined results from two randomized, double-blind, placebo-controlled Phase 3 studies. Psychopharmacol Bull. 2022;52:8\u201330.","journal-title":"Psychopharmacol Bull"},{"key":"3298_CR94","doi-asserted-by":"publisher","first-page":"19m12928","DOI":"10.4088\/JCP.19m12928","volume":"80","author":"M Fava","year":"2019","unstructured":"Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, et al. A Phase 2, Randomized, Double-blind, Placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). J Clin Psychiatry. 2019;80:19m12928.","journal-title":"J Clin Psychiatry"},{"key":"3298_CR95","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3233\/JPD-202058","volume":"10","author":"D DeKarske","year":"2020","unstructured":"DeKarske D, Alva G, Aldred JL, Coate B, Cantillon M, Jacobi L, et al. An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson\u2019s disease and depression. J Parkinsons Dis. 2020;10:1751\u201361.","journal-title":"J Parkinsons Dis"},{"key":"3298_CR96","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.1017\/S0033291722003579","volume":"53","author":"R Ahmed","year":"2023","unstructured":"Ahmed R, Boyd BD, Elson D, Albert K, Begnoche P, Kang H, et al. Influences of resting-state intrinsic functional brain connectivity on the antidepressant treatment response in late-life depression. Psychol Med. 2023;53:6261\u201370.","journal-title":"Psychol Med"},{"key":"3298_CR97","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2019.11.009","volume":"69","author":"S Horn","year":"2019","unstructured":"Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson\u2019s disease and dementia with lewy bodies. Parkinsonism Relat Disord. 2019;69:119\u201324.","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03298-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03298-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03298-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T03:51:09Z","timestamp":1742529069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03298-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3298"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03298-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.09.574871","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or the UK Department of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}